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Occasional Essay
Central Fat and Peripheral Muscle
Partners in Crime in Chronic Obstructive Pulmonary Disease
Bram van den Borst1, Harry R. Gosker1, and Annemie M. W. J. Schols1
1Department of Respiratory Medicine, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical
Center1, Maastricht, The Netherlands
According to the World Health Organization, by the year 2020,
chronic obstructive pulmonary disease (COPD) is expected to be
the third-leading cause of death, and it is the only major chronic
disease with an increasing mortality rate. Successful efforts to
reduce this mortality will require a better understanding of the
relationship between risk factors and the severity of the under-
lying lung disease. In patients with advanced disease, respiratory
failure is the most common cause of death and weight loss and
low muscle mass and strength are important determinants of
mortality (1). In these patients, the risk of death is remarkably
lower in obese patients. In contrast, in patients with mild-to-
moderate disease, the primary cause of death is ischemic cardio-
vascular disease, for which overweight and obesity are important
risk factors (2). The ongoing worldwide obesity epidemic neces-
sitates an enhanced understanding of the interactions between
cigarette smoke exposure, cardiovascular disease, skeletal muscle
dysfunction, and adiposity in patients with COPD. In this essay,
we discuss some of the mechanisms linking metabolism and ad-
iposity with clinical outcomes in patients with COPD and offer
tailored lifestyle interventions that may reduce morbidity and
mortality in these patients.
DRIVERS OF CARDIOVASCULAR AND METABOLIC RISK
IN COPD
Loss of Peripheral Skeletal Muscle Oxidative Phenotype
Muscle atrophy is highly prevalent in COPD irrespective of disease
severity (3, 4). In moderate-to-severe COPD, this atrophy is as-
sociated with a reduction in the activity of oxidative enzymes,
a decrease in mitochondrial density, impaired mitochondrial func-
tion, and a shift from fiber type I to type II (5). This loss of skeletal
muscle “oxidative phenotype” has been associated with muscle
fatigue (6) and decreased mechanical efficiency (7), and has also
been demonstrated in patients with mild-to-moderate COPD in
the absence of muscle atrophy (Figure 1) (8).
In diabetes, it has been proposed that skeletal muscle mito-
chondrial dysfunction may underlie peripheral insulin resistance
via complex mechanisms including oxidative stress, intramuscu-
lar lipid accumulation, and inflammation (9, 10). However, tests
of this hypothesis in human subjects have suggested that the
mitochondrial defect observed in the skeletal muscles of patients
with diabetes might be secondary to the insulin-resistant state
instead of being a causal factor (reviewed in Reference 11). This
notion is supported by striking parallels in skeletal muscle oxi-
dative phenotype between underweight/normal weight nondiabetic
patients with COPD and overweight/obese patients with diabetes.
For example, decreased mitochondrial respiration has also been
reported in patients with type 2 diabetes (12, 13), and the magni-
tude of reduced skeletal muscle peroxisome proliferator–activated
receptor-g coactivator-1a (PGC-1a) gene (the master regulator of
mitochondrial biogenesis) expression is comparable between non-
obese patients with COPD (8, 14) and obese subjects with type 2
diabetes (15). Also, several studies have shown evidence of a
decreased type I fiber proportion in overweight/obese patients
with type 2 diabetes compared with body mass index (BMI)-
matched control subjects (16, 17). The decreased oxidative capac-
ity of the skeletal muscle has been suggested to play a major role
in “metabolic inflexibility” (18), which is defined by a reduced
capacity to increase fat oxidation in response to increased fatty
acid availability and an impaired switch from fat to glucose as the
primary fuel source after a meal. Metabolic inflexibility may lead
to the accumulation of intramyocellular lipids, which has been
associated with insulin resistance through mechanisms possibly
involving the lipid intermediates ceramides and diacylglycerol,
which interfere with insulin signaling pathways (19). In the case
of high caloric intake and lack of physical exercise, a positive
energy balance may then further enhance ectopic fat deposition.
Investigators have employed homeostatic modeling of insulin
resistance (homeostatic model assessment [HOMA] index) to
show that insulin sensitivity is lower in nonobese and nondiabetic
patients with COPD compared with BMI-matched healthy con-
trol subjects (20–22). TheHOMA index, however, primarily reflects
hepatic insulin sensitivity, whereas skeletal muscle insulin sen-
sitivity can be most accurately assessed with the euglycemic insulin
clamp technique. Therefore, clamp studies are indicated to prove
or dispute that a decreased skeletal muscle oxidative phenotype is
associated with insulin resistance at the level of skeletal muscle in
COPD, as it is in diabetes.
Visceral Obesity
Several groups of investigators have suggested that low-grade sys-
temic inflammation characteristic of a number of diseases, including
COPD, is associated with an increased risk for the development of
atherosclerosis and ischemic cardiovascular events (23). There is
increasing evidence that adipose tissue is a significant contributor
to the systemic inflammatory load in COPD. For example, a persis-
tent systemic inflammation phenotype was described in patients
with COPD and was associated with the BMI but not with the
fat-free mass index, suggesting an inflammatory role for adipose
tissue (24). Moreover, in a subgroup of patients with COPD, low-
grade systemic inflammation has been positively related to total
abdominal fat mass (25). Thus, adipose tissue dysfunction, including
enhanced adipose tissue inflammation, may contribute to low-grade
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systemic inflammation in patients with COPD with absolute or rel-
ative fat abundance.
Abdominal visceral fat appears to be more strongly associated
than subcutaneous fat with risk factors for cardiovascular and
metabolic disorders, including hypertension and insulin resistance
(26, 27), and is receiving increasing attention in COPD. Indeed,
two studies have reported excessive visceral fat mass in nonobese
patients with mild-to-moderate COPD as detected by computed
tomography (CT) scanning (Figure 2) (28, 29). Moreover, exces-
sive visceral fat mass was positively associated with circulating
IL-6 levels, which were strongly associated with all-cause and
cardiovascular disease mortality (28). Importantly, excessive vis-
ceral fat mass in these patients with COPD existed in the absence
of obesity or increased abdominal circumference compared with
the control persons in these studies, suggesting enhanced fat ac-
cumulation specifically in the visceral compartment. It is unclear
whether the pulmonary impairment per se or an overall poor
lifestyle, or both, predispose to excessive visceral fat accumulation.
A similar selective increase in visceral fat mass has been observed
in other chronic diseases characterized by tissue inflammation in-
cluding rheumatoid arthritis, Crohn’s disease, and psoriasis. These
intriguing findings suggest a link between inflammation, visceral
fat, and cardiovascular risk. Careful mechanistic studies will be
required to determine whether an increase in visceral fat plays
a causal role in this chain.
The inflammatory capacity of visceral fat is considerably greater
than that of subcutaneous fat, and it has been suggested that visceral
fat is an important source of IL-6 and IL-1b (30). In addition, there is
evidence that an increase in visceral relative to subcutaneous fat is
associated with hypertriglyceridemia and a decreased rate of glucose
utilization in obese humans (31). Differential expression of the fat
mass and obesity associated (FTO) gene has been associated with
the differential deposition of fat in the visceral or subcutaneous
stores, adipose tissue inflammation, and differences in the expression
of inflammatory and insulin resistance–related genes in visceral com-
pared with subcutaneous fat in otherwise healthy overweight/obese
subjects (32). Consistent with the hypothesis that this gene may
contribute to obesity-related inflammation in patients with COPD,
single-nucleotide polymorphisms in the FTO gene were reported to
be positively associated with BMI in patients with COPD (33).
Increased visceral fat mass has been associated with increased
portal drainage of free fatty acids and adipokines to the liver,
which may induce hepatic insulin resistance, inflammation, and
oxidative stress (“portal hypothesis” [34]). Furthermore, visceral
adiposity has been associated with fat deposition in other unde-
sirable sites such as the liver, the heart, and the skeletal muscle
(35). To date, there are no data available about whether ectopic
fat deposition plays a role in the risk of cardiovascular and met-
abolic disease in COPD, but it may be involved in those with
increased visceral fat mass.
There is increasing evidence that components of the metabolic
syndrome are more prevalent in overweight patients with mild-to-
moderate COPD compared with BMI-matched control subjects. A
study reported that in overweight patients with COPD, 47% had
the metabolic syndrome compared with 21% in BMI-matched
Figure 2. Excessive visceral fat accumulation but normal
subcutaneous fat content in chronic obstructive pulmo-
nary disease (COPD). Abdominal computed tomography
(CT) scans from (A) a healthy person and (B) a patient with
COPD (FEV1, 53% of predicted) matched for age, sex, and
body mass index (29 kg/m2). The black and white areas in
C and D denote the visceral and subcutaneous fat com-
partments, respectively. Pictures show representative CT
scans from a previous study (28).
Figure 1. Peripheral muscle type I-to-II fiber shift, as an example of loss
of oxidative phenotype in chronic obstructive pulmonary disease
(COPD). Representative myosin heavy chain ATPase stainings of quad-
riceps muscle biopsies from (A) a healthy person and (B) a patient with
COPD (FEV1, 67% of predicted) matched for age, sex, and body mass
index (25 kg/m2). Black fibers indicate type I fibers and dark and light
gray fibers correspond with type IIX and type IIA fibers, respectively.
Pictures show representative photos from a previous study (8).
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healthy subjects (36). In another study of 170 German patients with
COPD, 53% of patients with moderate COPD (i.e., Global Initia-
tive for Chronic Obstructive Lung Disease [GOLD] classification
level II) met the criteria for metabolic syndrome and as much as
83% fulfilled the criteria for abdominal obesity (37). Congruently,
a large population study showed that those with airflow obstruction
had greater odds of having metabolic syndrome when adjusted for
BMI, and when its components were further analyzed only abdom-
inal obesity was significantly related to airflow obstruction (38).
LIFESTYLE INTERVENTION TO REDUCE THE RISK
OF CARDIOVASCULAR AND METABOLIC DISEASE
IN PATIENTS WITH COPD
Smoking Cessation
It is well known that smoking is an independent risk factor for
both COPD and cardiovascular disease. Less recognized is that
smokers have more central adiposity (39) and exposure to smok-
ing is associated with poor skeletal muscle function (40). Data
show that smokers are characterized by decreased skeletal mus-
cle insulin sensitivity, which was partially reversible on smoking
cessation. Experimental evidence suggests involvement of skele-
tal muscle mammalian target of rapamycin (mTOR) in this pro-
cess, a crucial regulator of cellular protein synthesis (41). BMI, as
well as whole-body muscle and fat masses, are comparably re-
duced in older patients with mild-to-moderate COPD and age-
matched smokers without COPD compared with nonsmokers,
suggesting a common insult earlier in life related to smoking
(4). Furthermore, the peripheral skeletal muscle of smokers
without COPD shows a loss of oxidative phenotype compared
with nonsmoking healthy control subjects (42). Smoking induces
low-grade systemic inflammation, independently of COPD (43),
and the persistent systemic inflammation observed in patients
with COPD was predicted by current smoking status (24). No-
tably, chronic exposure of mice to cigarette smoke also induces
systemic inflammation and decreased skeletal muscle oxidative
capacity (44). Smoking cessation is associated with fat mass gain,
particularly in the visceral compartment (45), stressing the need
for broad lifestyle interventions beyond smoking cessation.
Physical Activity and Aerobic Exercise Training
The Centers for Disease Control and Prevention and the Amer-
ican College of SportsMedicine recommend that a person should
engage in at least 30 minutes of moderate-to-vigorous physical
activity each day, preferably in bouts of 10 minutes or more
(46). The majority of patients with COPD have a sedentary
lifestyle (5) and physical inactivity contributes to the risk and
mortality associated with cardiovascular and metabolic disease.
Patients with COPD, irrespective of disease severity, have fewer,
shorter, and less intense periods of intense physical activity, and
spend more time at rest compared with healthy subjects (8). It
has been argued that the reduced level of physical activity is
causally implicated in the development of COPD, as studies have
consistently reported attenuated FEV1 decline in physically ac-
tive persons (smokers and nonsmokers) (47).
Bed-rest studies in healthy, lean subjects have shown that
physical inactivity induces a wide array of metabolic abnormal-
ities including skeletal muscle insulin resistance, impaired skel-
etal muscle lipid trafficking, a shift in fuel metabolism in favor of
carbohydrate oxidation and in detriment of lipid oxidation, an
increase in intramyocellular lipid content, muscle atrophy and
muscle fiber type I-to-II shift, and increased plasma nonesterified
fatty acid levels (48). As many of these metabolic abnormalities
have also been found in COPD, the adverse effects of physical
inactivity are likely to be substantial.
The benefits of aerobic exercise training on cardiometabolic
health have been well described in overweight or obese adults with
and without type 2 diabetes, but have been incompletely studied in
patients with COPD. In healthy overweight or obese adults, aerobic
exercise training improves insulin sensitivity and induces mitochon-
drial biogenesis in the skeletal muscle (49, 50), and induces the loss
of visceral fat mass (51). These effects were observed even in
patients whose body mass or waist circumference did not change.
Classically, it was assumed that aerobic exercise training in-
tensity in COPD could not reach the levels required to induce
physiological effects because of ventilatory limitation. Two im-
portant papers disputed this assumption by showing improved
lactate-to-work ratios and increased activity of key mitochon-
drial enzymes in muscle biopsies after aerobic exercise training
(52, 53), and these findings have been subsequently confirmed.
Arterial stiffness is an independent cardiovascular risk factor,
which is also improved by aerobic exercise training in healthy
subjects (54). Increased arterial stiffness has been reported in
patients with COPD, particularly those with advanced disease
(55). Interestingly, Vivodtzev and colleagues reported that a rel-
atively short aerobic exercise training program improved arte-
rial stiffness and quadriceps muscle endurance in a cohort of
patients with COPD (56). Gale and colleagues (57) showed that
standard multidisciplinary pulmonary rehabilitation including
aerobic exercise training reduced arterial stiffness without chang-
ing BMI in mildly overweight patients with COPD.
Diet and Nutritional Modulation
While weight gain and improved nutrition are recommended for
underweight patients with COPD (58), there is no systematic study
demonstrating efficacy of improved nutrition or weight reduction
strategies in overweight or obese patients with COPD. It seems
likely that the obesity paradox has limited enthusiasm for this ap-
proach. However, data from weight loss interventions in patients at
risk for diabetes suggest that even modest reductions in weight can
reduce the risk of cardiovascular and metabolic diseases, perhaps
through improvements in body fat distribution. For example, an
approximately 2–5% loss of body mass was reported to be associ-
ated with a sustained and preferential loss of visceral relative to
subcutaneous fat in otherwise healthy overweight or obese persons;
however, weight loss greater than 5% was associated with the loss
of fat in both compartments (59).
Dietary factors have also been put forward as contributing en-
vironmental factors in COPD etiology and pathology. A diet rich in
fruit, vegetables, whole-meal cereals, and fish is associatedwith a re-
duced COPD risk, whereas a “Western diet” rich in refined grains,
cured and red meats, desserts, and French fries is associated with
increased COPD risk, independent of smoking (60, 61). Further
study is required to identify the specific dietary components with
COPD risk as these strategies might be used to prevent the devel-
opment or slow the progression of COPD while simultaneously
reducing cardiovascular risk. The available literature suggests a par-
ticular important role for dietary fiber. There is convincing evi-
dence of lower fiber intake in patients with COPD (28) and that
increased dietary fiber intake is inversely associated with respira-
tory mortality (62). Dietary fiber has been shown to alter gut im-
munity and reduce systemic inflammation, which may be mediated
by alterations in the gut microbiome or other mechanisms. Poly-
unsaturated fatty acids (PUFAs) warrant further investigation in
targeted nutritional modulation as PUFAs (in particular n-3 fatty
acids) are known agonists of peroxisome proliferator–activated
receptors (PPARs), which are implicated in skeletal muscle ox-
idative gene expression. PUFA supplementation was also shown
to enhance training effects on exercise capacity in a randomized
controlled trial that included patients with moderate-to-severe
COPD (63). PPARs as potential targets for nutritional as well
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as pharmacological modulation in COPD have been discussed
in detail elsewhere (64).
Another promising example of nutritional modulation to im-
prove the cardiovascular andmetabolic disease risk profile inCOPD
is resveratrol, a natural polyphenolic compound in nuts and grapes
that is widely available as a nutritional supplement. Resveratrol
supplementation (150mg/d) has emerged as a calorie restrictionmi-
metic with beneficial cardiovascular, antiaging, and antidiabetogenic
properties in otherwise healthy overweight or obese men (65).
Interestingly, pharmacological inhibition of phosphodiesterase-4
reproduced all of the metabolic benefits of resveratrol in experi-
mental studies, likely through the same potential mechanisms.
These include elevation of intracellular cAMP levels, thereby in-
creasing NAD1 and the activity of SirT1, which in concert provide
a drive for increasing oxidative metabolism (66).
CONCLUSIONS
Adverse metabolic health, in terms of loss of peripheral skeletal
muscle oxidative phenotype and excessive visceral fat accumu-
lation, is associated with increased morbidity and mortality in
patients with COPD. This increased risk is evident at all stages
of the disease and is not necessarily restricted to obese patients.
Ruderman and colleagues described this phenotype as a “meta-
bolically obese, but normal weight person” (67). Physical inac-
tivity, poor dietary quality, and smoking contribute to these
metabolic abnormalities, and in concert further increase the risk
of cardiovascular morbidity and mortality (Figure 3).
Because loss of muscle oxidative phenotype and excessive vis-
ceral fat accumulation can exist without changes in muscle mass
and abdominal circumference, there is a need for new diagnostic
tools and biomarkers to reveal these hidden phenomena. Quad-
riceps muscle endurance tests or the lactate response on exercise
mayprovide good indicators of skeletalmuscle oxidative phenotype,
and abdominal bioelectrical impedance, ultrasound, and plasma lev-
els of the prothrombotic adipokine plasminogen activator inhibitor-
1 have shown good correlations with CT-acquired visceral fat mass
but require validation in COPD.
The most important question that needs to be answered in fu-
ture studies is whether the adverse metabolic profile in patients
with COPD is caused by the disease itself or by an overall poor
lifestyle, and whether the two act synergistically. Studies in patients
with COPD and control subjects without COPDmatched for over-
all lifestylemay help in disentanglingCOPD-specific versus lifestyle-
mediated influences. Other important questions remain: Is the loss
of peripheral skeletal muscle oxidative phenotype in COPD an ac-
celerator of or causally implicated in insulin resistance? Is there
a physiological link between the loss of peripheral skeletal muscle
oxidative phenotype and visceral fat accumulation? Is the inflamma-
tory status of visceral versus subcutaneous fat enhanced in COPD,
and does this relate to an adverse cardiovascular or metabolic pro-
file?What is the role of ectopic fat deposition in the adverse cardio-
vascular and metabolic profile in COPD? Finally, a possible link
between adipose hormones and pulmonary inflammation may shed
new light on the importance of adipose tissue in COPD progression
in the current obesogenic society.
It is projected that increased knowledge of the metabolic
changes in patients with COPD will allow investigators to test
interventions aimed at reducing the risk of cardiovascular and
metabolic diseases and their associated morbidity and mortality.
Available data suggest that the early implementation of tailored
lifestyle interventions in patients with COPD who are not yet
physically impaired is likely to be beneficial. These lifestyle fac-
tors extend beyond recommendations for smoking cessation; in-
stead, an integrated systems approach addressing smoking, physical
inactivity, and poor diet may be most beneficial in slowing the pro-
gression of the disease.
Author disclosures are available with the text of this article at www.atsjournals.org.
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